ANTI-LYVE1 ANTIBODY PRODUCED IN RABBIT (C15-1738-786)

General description

LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1) is a type I integral membrane polypeptide. It is present on lymph vessel endothelial cells of both normal and neoplastic tissues. LYVE consists of a single N-terminal HA binding domain. It is mapped to human chromosome 11p15.

Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), also known as CRSBP, is encoded by the gene localized on human chromosome 11p15.4. The encoded protein is mainly mapped to the plasma membrane as well as intracellular fibrillar structures in lymphatic endothelial cells (LECs), including primary human dermal LECs and SVEC4-10 cells. LYVE1 belongs to the link module superfamily of C-type lectins.

Immunogen

Peptide sequence around aa. 271-275 (K-N-Q-Q-K), according to the protein LYVE1.

Biochem/physiol Actions

LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1) plays an important role in hyaluronan homeostasis. It controls cellular trafficking of the lymph nodes. It serves as an important lymphatic vessel marker.

Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) induces activation of its ligand, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF)-A and hyaluronic acid, opens lymphatic intercellular junctions in vitro and in vivo by enhancing contraction of lymphatic endothelial cells (LECs). The encoded protein also facilitates uptake of hyaluronan (HA) and trafficking of leukocytes to draining lymph nodes.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Target description

Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as an hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.